MedPath

Efficacy and safety of bimatoprost in vitiligo: A randomized single-blinded controlled study

Phase 4
Recruiting
Conditions
Stable nonsegmental and segmental vitiligo lesions (for the last 3 months)
Vitiligo&#44
nonsegmental&#44
segmental
Registration Number
TCTR20170526002
Lead Sponsor
Department of dermatology, Siriraj Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
25
Inclusion Criteria

1. Stable nonsegmental and segmental vitiligo lesions (for the last 3 months)
2. Without received any local treatment for vitiligo for at least 2 weeks before the study
3. Without received any photo therapy for vitiligo for at least 4 weeks before the study

Exclusion Criteria

1. Photosensitive patients, those with light aggravated dermatoses
2. Pregnant
3. Lactating females and patients with asthma or hypertension

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Efficacy of bimatoprost in the treatment of vitiligo 8 months Photographs, VASI Score, Extent of repigmentation,Efficacy of bimatoprost combined with targeted NB-UVB in the treatment of vitiligo 8 months Photographs, VASI Score, Extent of repigmentation
Secondary Outcome Measures
NameTimeMethod
Safety of bimatoprost in the treatment of vitiligo 8 months Patients' evaluation
© Copyright 2025. All Rights Reserved by MedPath